MT · State regulatory reference
Montana.
Moderate
Montana tracks the federal 503A/USP framework without a distinctive restrictive rule and has no located state-board enforcement targeting peptide or GLP-1 compounding. Telemedicine is governed by MCA Title 37, ch. 3 (definitions at 37-3-102) and Mont. Admin. R. 24.156.813, which permit establishing a provider-patient relationship and prescribing entirely via telemedicine when the standard of care does not require an in-person encounter. The Board of Pharmacy expects compounders to follow USP <795> (nonsterile) and <797> (sterile), with sterile-compounding standards at ARM 24.174.841; no Montana-specific GLP-1/semaglutide restriction was found.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
Under Mont. Admin. R. 24.156.813, a physician may establish the provider-patient relationship and prescribe (including via an initial synchronous audio-video visit) if the standard of care does not require an in-person encounter; Montana's statutory 'telemedicine' definition excludes audio-only, so a first visit generally needs interactive audio-video.
Compounding
Montana has no peptide- or GLP-1-specific compounding rule; the Board of Pharmacy applies USP <795>/<797> standards (sterile compounding at ARM 24.174.841), leaving GLP-1 compounding governed chiefly by federal 503A and FDA shortage-list rules.
Sources